Haematologica · 2012 · 61 citations · 37 references
MedicinePharmacologyPharmacotherapyChemotherapyClinical PharmacologyMedical OncologyChemotherapy In Hematologic MalignanciesCombination ChemotherapyDose SchedulingHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentAdult Hematologic Malignancy ChemotherapyDisease-free Survival AnalysisDisease-free Survival AssessmentMitoxantrone TherapyPhase Ii InvestigationStudy Phase
BACKGROUND: Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13.6 months. DESIGN AND METHODS: We compared bolus flavopiridol (50 mg/m(2)/day, Arm A) versus 'hybrid' flavopiridol (30 mg/m(2) over 30 min followed by 40 mg/m(2) over 4 h, Arm B) followed by ara-C and mitoxantrone in 78 patients (39 per arm) with newly diagnosed, poor-risk acute myelogenous leukemia. To mitigate imbalance, patients were stratified by presence or absence of secondary leukemia and therapy for antecedent disorder. RESULTS: Death at or before Day 60 occurred in 8% of patients per arm. Complete remission plus complete remission with incomplete recovery was 68% (Arm A, 62%; Arm B, 74%) overall, and 65% or over in both arms for patients with secondary leukemia and leukemia with adverse genetics. In Arm A 91% and in Arm B 86% of patients received chemotherapy and/or allogeneic transplantation in complete remission. Median overall survival for all remission patients has not been reached for either arm, with median disease free survival of 13.6 months for Arm A and of 12.0 months for Arm B. CONCLUSIONS: Both flavopiridol schedules produce comparably encouraging results in adults with poor-risk acute myelogenous leukemia. Given the greater ease of bolus administration, we are conducting a randomized phase II study of bolus flavopiridol followed by ara-c and mitoxantrone versus conventional induction therapy for patients aged 70 years and under with intermediate or poor-risk acute myelogenous leukemia. This study is registered at www.clinicaltrials.gov as #NCT 00407966.
37
John C. Byrd · Blood · 2002 · 1.6K citations
Medicine, Hematology, Oncology +16
Age and acute myeloid leukemia
Frederick R. Appelbaum, Holly Gundacker, David R. Head et al. · Blood · 2006 · 1.3K citations · Full text
Medicine, Hematology, Oncology +12
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernández, Zhuoxin Sun, Xiaopan Yao et al. · New England Journal of Medicine · 2009 · 907 citations · Full text
Medicine, Oncology, Pharmacotherapy +13